Intra-arterial infusion: Overview and novel approaches

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 248-253

  Aigner, K R ^a,b  

^a Asklepios Paulinen Klinik   (Germany)

^b Abteilung fur Chirurgische Onkologie   (Germany)

Author keywords

Antineoplastic agents; Breast neoplasms; Drug dose response relationship; Intra arterial infusions; Mammary arteries; Pancreatic neoplasms; Quality of life; Regional perfusion; Remission induction; Stopflow procedure; Subclavian artery; Survival rate; Therapeutic chemoembolization

Indexed keywords

FLOXURIDINE; FLUOROURACIL; MITOMYCIN C; STARCH MICROSPHERE;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; IMPLANTABLE PORT SYSTEM; INTRAARTERIAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER PERFUSION; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; TARGET ORGAN; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES;

EID: 0031943225     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<248::AID-SSU9>3.0.CO;2-8     Document Type: Article

References (41)

1. Hohn DC, Shea WJ, Gemlo BT, et al: Complications and toxicities of hepatic arterial chemotherapy. Contr Oncol 1988;29:169-180.
2. Pettavel J, Gardiol D, Bergier N, et al: Necrosis of main bile ducts caused by hepatic artery infusion of 5-fluoro-2-deoxyuridine. Reg Cancer Treat 1988;1:83-92.
3. Sullivan RD, Zurek WZ: Chemotherapy for liver cancer by protracted ambulatory infusion. JAMA 1965;194:481-486.
4. Watkins E Jr, Sullivan RG: Cancer chemotherapy by prolonged arterial infusion. Surg Gynecol Obstet 1964;118:3-19.
5. Muller H, Aigner KR, Palliation of recurrent rectal cancer with intraarterial mitomycin c/5-fluorouracil via Jet Port aortic bifurcation catheter. Reg Cancer Treat 1990;3:147-151.
6. Aigner KR, Gailhofer S: High dose MMC-aortic stopflow infusion (ASI) with vs. without chemofiltration - a comparison of toxic side effects [Abstract]. Reg Cancer Treat 1993;6(Suppl 1):3.
7. Aigner KR: Aortic stopflow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulky peritoneal carcinomatosis - rationale and technique. Reg Cancer Treat 1993;6(Suppl 1):3.
8. Aigner KR, Kaevel K: Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer Treat 1994;7:6-11.
9. Chang A, Schneider R, Sugerbaker P, et al: A prospective randomized trial of regional vs. systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-693.
10. Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous vs. hepatic intra-arterial floxuridine in patients with colorectal cancer metastatic to the liver the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646-1654.
11. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal cancer. Ann Intern Med 1987;107:459-465.
12. Martin JK Jr, O'Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 1990;125: 1022-1027.
13. Rougier PH, Laplanche A, Haguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial [comment in J Clin Oncol 1992;10:1986-1988]. J Clin Oncol 1992;10:1112-1118.
14. Bengmark S, Peterson-Dahl E, Fredlund PE, Hepatic dearterialization and infusion treatment of liver tumors. In Peterson HI (ed): "Tumor blood circulation: angiogenesis, vascular morphology and blood flow of experimental and human tumors." Boca Raton, FL: CRC Press; 1979. p. 203-216.
15. Coldwill DM, Mortimer JE, Hepatic artery embolization in the treatment of hepatic malignancies. Reg Cancer Treat 1991;3:298-301.
16. Daniels JR, Kerlan RK Jr, Dodds L, et al: Peripheral hepatic arterial embolization with cross-linked collagen beads. Invest Radiol 1987;122:126-131.
17. El Domeiri AA: A method for intermittent occlusion and chemotherapy infusion of the hepatic artery. Surg Gynecol Obstet 1976;43:107-109.
18. Taguchi T, Ogawa N, Bunke B, et al: The use of degradable starch microspheres (Spherex) with inra-arterieal chemotherapy for the treatment of primary and secondary liver tumors. Results of a phase III clinical trial. Reg Cancer Treat 1992;4:161-I65.
19. Venook A, Stagg R, Louis B, et al: Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990;8:1108-1114.
20. Civalleri D, Rollandi G, Simoni G, et al: Redistribution of arterial blood flow in metastases-bearing livers after infusion of degradable starch microspheres. Acta Chir Scand 1985;151: 613-617.
21. Civalleri D, Scopinaro G, Simoni G, et al: Starch microspheres induced arterail flow redistribution after occlusion of replaced hepatic arteries in patients with liver metastases. Cancer 1986; 58:2151-2155.
22. Hakansson L, Hakansson A, Morales O, et al: Spherex (degradable starch microspheres) chemo-occlusion-enhancement of tumor drug concentration and therapeutic efficacy: an overview. Semin Oncol 1997;24(Suppl 6):100-109.
23. Aigner KR, Müller H, Time dependent cisplatinum (CDDP) tissue concentrations after hepatic artery infusion of CDDP with (HAI-Spherex) and without (HAI) starch microspheres. In Hottenrott C, Quick L (eds): "Excerpt from a workshop on SPHEREX in locoregional cancer treatment." Helsingborg, Germany: Bergstens Grafiska; 1990. p. 9-11.
24. Civalleri D, Esposito M, Fulco RA, et al: Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases. 1991;Cancer 68:988-994.
25. Aigner KR, Müller H, Bassermann R: Intra-arterial chemotherapy with MMC, CDDP and 5-FU for nonresectable pancreatic cancer - a phase II study. Reg Cancer Treat 1990;3:1-6.
26. Aigner KR, Benthin F, Müller H: Celiac axis infusion (CAI) chemotherapy for advanced gastric cancer. In Sugarbaker PH (ed): "Management of gastric cancer." Boston: Kluwer Academic; 1991. p. 357-362.
27. Stephens FO, Management of gastric cancer with regional chemotherapy preceding gastrectomy: 5-year survival results. Reg Cancer Treat 1988;1:80-82.
28. Aigner KR, Walther H, Müller H, et al: Intra-arterial infusion chemotherapy for recurrent breast cancer via an implantable system, Reg Cancer Treat 1988;1:102-107.
29. Aigner KR, Müller H, Chatzissavidis J: Subclavian artery infusion for locally recurrent breast cancer - a review on 144 patients [Abstract]. Reg Cancer Treat 1993;6(Suppl 1):3.
30. Aigner KR, Thiem N: Regional chemotherapy for recurrent breast cancer - the effect of different techniques of drug administration on tumor response. Reg Cancer Treat 1994;7:127-131.
31. Averbach AM, Stuart OA, Sugarbaker TA, et al: Intraarotic stopflow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers. Ann Surg Oncol 1995;2:325-331.
32. Averbach AM, Stuart OA, Sugarbaker TA, et al: Pharmacokinetic studies of intraaortic stop-flow infusion with 14C-labeled mitomycin C. J Surg Res 1995;59:415-419.
33. Thompson JF, Waugh RC, Kamp P: Stop-flow cytoxic infusion. A simplified technique using percutaneous catheters. Reg Cancer Treat 1993;6(Suppl 1):51-52.
34. Thompson JF, Liu M, Waugh RC, et al: A percutaneous aortic "stopflow" infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat 1994;7:202-207.
35. Rockwell S: Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 1986;38:229-235.
36. Teicher BA, Lazo JS, Sartorelli AC: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81.
37. Aigner KR, Müller H, Walther H, Link KH: Drug filtration in high-dose regional chemotherapy. Contr Oncol 1988;29:261-280.
38. Aigner KR, Gailhofer S, Müller H: Regional chemotherapy of advanced pancreatic cancer with Mitoxantron-Spherex and Mitomycin-chemofiltration. In Klapdor R (ed): "Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties." W. Zuchschwerdt Verlag München, 1991, 692-696.
39. Aigner KR, Gailhofer S, Kopp S: Regional vs. systemic chemotherapy for advanced pancreatic cancer - a randomized study. Hepatogastroenterology. In press.
40. Aigner KR, Gailhofer S: Regional chemotherapy for pancreatic cancer - a review on 242 cases. Reg Cancer Treat. In press.
41. Link KH, Staib L, Beger HG: Influence of exposure concentration and exposure time cxt on toxicity of cytostatic drugs to HT 29 human colorectal carcinoma cells. Characterization of drugs for (regional) chemotherapy. Reg Cancer Treat 1989;2:189-197.